NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 292 filers reported holding NOVOCURE LTD in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,391 | +20.0% | 148 | +208.3% | 0.00% | – |
| Q2 2023 | $1,992 | -82.2% | 48 | -74.2% | 0.00% | -100.0% |
| Q1 2023 | $11,187 | -42.9% | 186 | -30.3% | 0.00% | -50.0% |
| Q4 2022 | $19,584 | -34.7% | 267 | -32.2% | 0.00% | -50.0% |
| Q3 2022 | $30,000 | -3.2% | 394 | -12.4% | 0.00% | 0.0% |
| Q2 2022 | $31,000 | -38.0% | 450 | -25.1% | 0.00% | -33.3% |
| Q1 2022 | $50,000 | +212.5% | 601 | +175.7% | 0.01% | +200.0% |
| Q4 2021 | $16,000 | +166.7% | 218 | +327.5% | 0.00% | +100.0% |
| Q3 2021 | $6,000 | -81.8% | 51 | -65.3% | 0.00% | -80.0% |
| Q2 2021 | $33,000 | +230.0% | 147 | +104.2% | 0.01% | +150.0% |
| Q1 2021 | $10,000 | +900.0% | 72 | +928.6% | 0.00% | – |
| Q4 2020 | $1,000 | – | 7 | +75.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 4 | -94.7% | 0.00% | -100.0% |
| Q3 2019 | $5,000 | – | 76 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |